Acasti Pharma Inc.
ACST
$0.06
Change (1 day)
$3.59
Year High
$1.98
Year Low
Categories
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Revenue of Acasti Pharma Inc. (ACST)
Revenue in 2023 (TTM): $
According to Acasti Pharma Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Acasti Pharma Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-11,000 | $-11,301,000 | $-14,630,000 | $-12,853,000 |
| 2022 | $ | $-52,155,000 | $15.85 M | $-51,971,000 | $-42,429,000 |
| 2021 | $ | $-15,589,000 | $-19,989,000 | $-10,467,000 | $-9,819,000 |
| 2020 | $196 K | $120 K | $-9,949,000 | $-19,678,000 | $-19,678,000 |
| 2019 | $ | $-2,320,000 | $-21,828,000 | $-25,513,000 | $-25,760,000 |
| 2018 | $ | $-2,333,000 | $-30,988,616 | $-38,620,431 | $-43,861,594 |
| 2017 | $ | $ | $-14,007,945 | $-16,651,567 | $-16,942,722 |
| 2016 | $ | $ | $ | $ | $ |
| 2015 | $27.79 K | $-32,294 | $-5,271,488 | $-4,661,416 | $-4,661,416 |
| 2014 | $216.29 K | $28.39 K | $-7,970,323 | $-1,322,541 | $-1,322,541 |
| 2013 | $450.16 K | $187.86 K | $-9,087,226 | $-10,435,936 | $-10,435,936 |
| 2012 | $707.4 K | $310.45 K | $-6,122,063 | $-6,732,464 | $-6,732,464 |
| 2011 | $127.11 K | $122.01 K | $-5,835,483 | $-6,538,661 | $-6,538,661 |
| 2010 | $29.04 K | $29.04 K | $-2,424,116 | $ | $-2,426,846 |
| 2009 | $ | $ | $-1,529,677 | $-1,527,334 | $-1,508,303 |